Agency Information Collection Activities: Proposed Collection; Comment Request, 56875-56878 [2024-15250]
Download as PDF
Federal Register / Vol. 89, No. 133 / Thursday, July 11, 2024 / Notices
56875
TABLE III—TEST INFORMATION RECEIVED FROM 5/01/2024 TO 5/31/2024—Continued
Case No.
Received
date
P–24–0135 .............................
04/19/2024
P–24–0135 .............................
04/19/2024
P–24–0135 .............................
04/19/2024
Type of test Information
Acute Oral Toxicity—Fixed Dose Method (OECD Test
Guideline 420); In Vitro Skin Irritation (OECD Test
Guideline 439); Bovine Corneal Opacity and Permeability Assay (OECD Test Guideline 437); Skin Sensitization: Local Lymph Node Assay (OECD Test
Guideline 429).
Melting Point/Melting Range (OECD Test Guideline 102);
Boiling Point/Boiling Range (OECD Test Guideline
103); Density/Relative Density/Bulk Densit (OECD Test
Guideline 109); Surface Tension of Aqueous Solutions
(OECD Test Guideline 115); Water Solubility: Column
Elution Method; Shake Flask Method (OECD Test
Guideline 105), Partition Coefficient (n-octanol/water),
Estimation by Liquid Chromatography (OECD Test
Guideline 117); Hydrolysis (OECD Test Guideline 111);
Dissociation Constants in Water (OECD Test Guideline
112); Estimation of the Adsorption Coefficient (Koc) on
Soil and on Sewage Sludge using High Performance
Liquid Chromatography (HPLC) (OECD Test Guideline
121); Hazardous Physical Chemical Property Testing;
Vapor Pressure (OECD Test Guideline 104); Flammability (OCSPP Test Guideline 830.6315).
Fish, Early-Life Stage Toxicity Test (OECD Test Guideline
210); Daphnia sp., Acute Immobilization Test (OECD
Test Guideline 202); Daphnia magna Reproduction
Test (OECD Test Guideline 211); Freshwater Alga and
Cyanobacteria, Growth Inhibition Test (OECD Test
Guideline 201); Activated Sludge, Respiration Inhibition
Test (Carbon and Ammonium Oxidation) (OECD Test
Guideline 209).
If you are interested in information
that is not included in these tables, you
may contact EPA’s technical
information contact or general
information contact as described under
FOR FURTHER INFORMATION CONTACT to
access additional non-CBI information
that may be available.
Dated: July 8, 2024.
Todd Holderman,
Acting Director, Project Management and
Operations Division, Office of Pollution
Prevention and Toxics.
[FR Doc. 2024–15255 Filed 7–10–24; 8:45 am]
BILLING CODE 6560–50–P
FEDERAL RESERVE SYSTEM
khammond on DSKJM1Z7X2PROD with NOTICES
Formations of, Acquisitions by, and
Mergers of Savings and Loan Holding
Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Home Owners’ Loan Act
(12 U.S.C. 1461 et seq.) (HOLA),
Regulation LL (12 CFR part 238), and
Regulation MM (12 CFR part 239), and
all other applicable statutes and
regulations to become a savings and
loan holding company and/or to acquire
the assets or the ownership of, control
of, or the power to vote shares of a
savings association.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
VerDate Sep<11>2014
19:08 Jul 10, 2024
Jkt 262001
Chemical substance
(S) Phosphoric acid, mono- and di-c16–18-alkyl esters.
(S) Phosphoric acid, mono- and di-c16–18-alkyl esters.
(S) Phosphoric acid, mono- and di-c16–18-alkyl esters.
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on
whether the proposed transaction
complies with the standards
enumerated in the HOLA (12 U.S.C.
1467a(e)).
Comments received are subject to
public disclosure. In general, comments
received will be made available without
change and will not be modified to
remove personal or business
information including confidential,
contact, or other identifying
information. Comments should not
include any information such as
confidential information that would not
be appropriate for public disclosure.
Comments regarding each of these
applications must be received at the
Reserve Bank indicated or the offices of
the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th
Street and Constitution Avenue NW,
Washington, DC 20551–0001, not later
than August 12, 2024.
A. Federal Reserve Bank of Cleveland
(Nadine M. Wallman, Vice President)
1455 East Sixth Street, Cleveland, Ohio
44101–2566. Comments can also be sent
electronically to
Comments.applications@clev.frb.org:
1. Monroe Federal Bancorp, Inc., Tipp
City, Ohio; to become a savings and loan
holding company by acquiring Monroe
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
Federal Savings and Loan Association,
Tipp City, Ohio, in connection with the
mutual-to-stock conversion of Monroe
Federal Savings and Loan Association.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2024–15268 Filed 7–10–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve a revision of the
currently approved information
collection project: ‘‘The AHRQ Safety
Program for Telemedicine: Improving
the Diagnostic Process and Improving
Antibiotic Use.’’
This proposed information collection
was previously published in the Federal
Register on April 29th, 2024 and
allowed 60 days for public comment.
AHRQ received no substantive
SUMMARY:
E:\FR\FM\11JYN1.SGM
11JYN1
56876
Federal Register / Vol. 89, No. 133 / Thursday, July 11, 2024 / Notices
comments from members of the public.
The purpose of this notice is to allow an
additional 30 days for public comment.
DATES: Comments on this notice must be
received by August 12, 2024.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
Copies of the proposed collection
plans, data collection instruments, and
specific details on the estimated burden
can be obtained from the AHRQ Reports
Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
email at
REPORTSCLEARANCEOFFICER@
ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
Proposed Project
khammond on DSKJM1Z7X2PROD with NOTICES
AHRQ Safety Program for Telemedicine:
Improving Antibiotic Use
This Information Collection Request
(ICR) is for a revision to the AHRQ
Safety Program for Telemedicine:
Improving the Diagnostic Process and
Improving Antibiotic Use. These
changes include the removal of the
Diagnostic Process Cohort, updates to
the Improving Antibiotic Use Data
Collection Tools and changing the name
of the project to the ‘‘AHRQ Safety
Program for Telemedicine: Improving
Antibiotic Use.’’ The OMB control
number for the AHRQ Safety Program
for Telemedicine is 0935–0265 and will
expire on April 30, 2026. Supporting
documents can be downloaded from
OMB’s website at: https://
www.reginfo.gov/public/do/
PRAViewICR?ref_nbr=202303-0935-001.
AHRQ is requesting a new expiration
date, three years from approval.
Since the project received OMB
approval, there have been two
developments that require changes to
the project’s goals and design. First, the
Improving the Diagnostic Process
Cohort was canceled because there was
insufficient recruitment. Second, the
materials approved by OMB for the
Improving Antibiotic Use Cohort
included a single version of the
Structural Assessment and Participant
Experience Survey, to be completed by
all participants in the improving
antibiotic use cohort. However,
following pre-recruitment discussions
VerDate Sep<11>2014
19:08 Jul 10, 2024
Jkt 262001
with AHRQ’s Technical Expert Panel
(TEP) and potential participants, it was
learned that the target audience for the
improving antibiotic use cohort is
comprised of healthcare providers from
two distinctly different settings (brickand-mortar and telemedicine-only)
settings. Providers that practice in brickand-mortar settings provide care both
in-person and via telemedicine whereas
providers that practice in telemedicineonly settings provide care exclusively
using telemedicine. Based on this
information AHRQ decided to create
separate data collection tools, one for
providers in a brick-and-mortar setting,
and one for providers in telemedicine
only. Practices and providers receive
information about the program from
newsletters, listservs, and direct
outreach through public and private
organizations. They attend an
information webinar and may join the
program if interested and eligible.
As in the currently approved design,
the program will incorporate CUSP
strategies to improve antibiotic
prescribing in telemedicine. The new
program goals are to:
• Identify best practices in
implementing interventions to improve
antibiotic use in telemedicine.
• Determine how best to adapt CUSP
to enhance antibiotic use in
telemedicine.
• Use a CUSP approach to design and
implement the interventions for
improving antibiotic use across
telemedicine practices.
• Reduce inappropriate antibiotic
prescribing among telemedicine
practices.
To achieve these goals the following
data collections will be implemented:
1. Structural Assessment Antibiotic
Use Cohort—There will be two versions
of the Structural Assessment, one for
providers in a brick-and-mortar setting,
and one for providers in telemedicine
only. Both versions ask the same
questions but vary slightly in how they
refer to the practice. The assessment
asks about the practice’s characteristics,
experience related to antibiotic
stewardship activities, and any existing
supports the practice may have in place
that are intended to improve antibiotic
prescribing. The assessment will be
administered to the Safety Program
leader/champion at each participating
brick-and-mortar practice or
telemedicine-only organization at
baseline (pre-intervention) and at the
end of the intervention. The results will
be used to assess changes in the
practice’s infrastructure and capacity to
implement the Safety Program over
time. The data will provide information
about any existing quality improvement
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
initiatives currently in place, their
existing infrastructure and capacity to
carry out the program, as well as
changes in the infrastructure and quality
improvement activities as a result of
participation in the Safety Program.
2. Medical Office Survey on Patient
Safety Culture (MOSOPS): As currently
approved, the Safety Program for
Telemedicine included completion of
the MOSOPS by all participating staff
across all participating practices. In this
revision, AHRQ will administer the
MOSOPS to HCPs practicing in brickand-mortar settings only. The MOSOPS
was designed to assess key
characteristics of HCPs working inperson in a single medical office and
results are unlikely to be reliable or
valid if administered among HCPs
practicing in telemedicine-only settings.
The MOSOPS will be administered to
all participating staff at brick-andmortar practices at baseline (preintervention) and at the end of the
intervention. The survey collects
information on patient safety issues,
patient safety culture, medical errors,
and event reporting. The data will be
used to assess changes in safety culture
following implementation of the Safety
Program.
3. Participant Experience Survey
Antibiotic Use Cohort—Based on
feedback from the TEP and
conversations with telemedicine-only
organizations, this revision includes
changes to the Participant Experience
Survey as well as unique versions for
brick-and-mortar and telemedicine-only
participants. The survey will be
administered to the clinical leader/
champion at each practice at the end of
the program (post-intervention). The
survey will assess how participants
approached implementation of the
Safety Program.
4. Semi-Structured Interviews
Antibiotic Use Cohort—A proportion of
practices from both brick-and-mortar
practices and telemedicine-only
organizations will be selected to
participate in telephone/virtual
discussions to understand the
facilitators and barriers to implementing
the Safety Program. This interview
guide includes four core domains that
are intended to capture characteristics
of health care providers (physicians,
nurse practitioners, and physician
assistants) and their perception of the
AHRQ Safety Program for Telemedicine:
Improving Antibiotic Use (‘‘the Safety
Program’’) on pre- and postimplementation changes. All interviews
will occur at the end of the intervention
period.
5. Antibiotic Prescription Data
Template Antibiotic Use Cohort—Each
E:\FR\FM\11JYN1.SGM
11JYN1
56877
Federal Register / Vol. 89, No. 133 / Thursday, July 11, 2024 / Notices
month starting at baseline (preintervention) until the end of the
intervention, each participating practice
will extract antibiotic prescribing data
from their electronic health record
(EHR) system. The data will be
submitted quarterly using a secure
online data submission portal. The
prescribing data will evaluate changes
in antibiotic usage, clinical outcomes,
and other effectiveness measures
resulting from participation in the
Safety Program. Based on feedback from
participants in the prior AHRQ Safety
Program, this updated version includes
revisions to the EHR template to
simplify the data requested in the
template from aggregate to visit-level.
Participating practices will submit two
key types of data related to antibiotic
prescribing: (1) Total antibiotic
prescriptions per 100 respiratory tract
infection telemedicine visits and (2)
Antibiotic prescriptions per 100
antibiotic-inappropriate respiratory tract
infection telemedicine visits. This data
will be an important way for the
practice to monitor its prescribing
practices throughout the course of the
program and will be used by the
assessment team to monitor and
describe prescribing trends across
practices enrolled in the program.
This study is being conducted by
AHRQ through its contractor, NORC at
the University of Chicago and Johns
Hopkins Medicine, pursuant to AHRQ’s
statutory authority to conduct and
support research on healthcare and on
systems for the delivery of such care,
including activities with respect to the
quality, effectiveness, efficiency,
appropriateness, and value of healthcare
services and with respect to quality
measurement and improvement. 42
U.S.C. 299a(a)(1) and (2).
Method of Collection
To minimize respondent burden and
to permit the electronic submission of
survey responses and data collection
forms, the structural assessment, AHRQ
MOSOPS, participant experience
survey, and antibiotic prescription data
template will be web-based and
deployed using a well-designed, low
burden, and respondent-friendly survey
administration process. In addition, the
EHR data extracted by practice staff that
are requested for this program may
already be collected by practices as part
of their ongoing quality improvement
initiatives. Practices will receive access
to the online data collection platform
and detailed instructions on completing
the online forms and EHR data
submissions.
Estimated Annual Respondent Burden
Exhibit 1 shows the estimated
annualized burden hours for the
respondents’ time to participate in this
project.
1. Structural Assessment Antibiotic
Use Cohort—The assessment will be
administered twice to the Safety
Program leader/champion at each
participating brick-and-mortar practice
or telemedicine-only organization, once
at baseline (pre-intervention) and again
at the end of the intervention. AHRQ
expects 188 respondents at each
administration. The Assessment
requires 12 minutes to complete.
2. Medical Office Survey on Patient
Safety (MOSOPS)—The MOSOPS will
be completed by all participating staff at
brick-and-mortar practices to assess
patient safety issues, medical errors, and
event reporting practices. The survey
will be completed twice, once at
baseline (pre-intervention) and at the
end of the intervention to measure the
changes in patient safety culture
resulting from participation in the
Safety Program. The survey will be
completed by 438 staff members at each
administration and requires 30 minutes
to complete.
3. Participant Experience Survey
Antibiotic Use Cohort—The Participant
Experience Survey will be administered
once to the Safety Program leader/
champion at the end of the intervention
to assess participant engagement and
progress; understand providers’
experience using materials and
participating in the Safety Program; and
identify processes used and changes
made to implement and sustain the
Safety Program. The survey is estimated
to require 20 minutes to complete.
4. Semi-Structured Interviews
Antibiotic Use Cohort—Semi-structured
interviews will be conducted at the end
of the intervention among clinical and
professional support staff from a sample
of practices to collect qualitative
information on the implementation of
the program. Interviews will be
conducted with 18 participating
practices/organizations and requires one
hour to complete.
5. Antibiotic Prescription Data
Template Antibiotic Use Cohort—The
Antibiotic Prescription Data Template
will be completed each month and
submitted quarterly starting in the
baseline (pre-intervention) period until
the end of the intervention to measure
changes in antibiotic usage resulting
from the intervention. The data will be
extracted from the practice/
organization’s electronic health records,
by a staff member, and entered into the
data template. AHRQ expects 225
practices/organizations to extract data
monthly for 18 months. Each monthly
data extraction should require one hour
of a staff members time.
The total burden for the respondents’
time to participate in this research is
estimated to be 4,644 hours.
EXHIBIT 1—ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents *
Form name
khammond on DSKJM1Z7X2PROD with NOTICES
1.
2.
3.
4.
5.
Number of
responses per
respondent
Hours per
response
Total burden
hours
Structural Assessment .................................................................................
MOSOPS (brick-and-mortar only) ...............................................................
Participant Experience Survey ....................................................................
Semi-structured interviews ..........................................................................
Antibiotic Prescription Data Template .........................................................
188
438
188
18
225
2
2
1
1
18
12/60
30/60
20/60
1
1
75
438
63
18
4,050
Total ..........................................................................................................
1,057
na
na
4,644
* Annualized number of respondents is based on maximum practices recruited, assuming 50% of the practices are telemedicine-only and 50%
are brick-and-mortar, and 75% response rate for forms 1 and 3, 50% response rate for form 2, and 90% response rate for forms 4 and 5.
Exhibit 2 shows the estimated
annualized cost burden based on the
respondents’ time to complete the data
VerDate Sep<11>2014
19:08 Jul 10, 2024
Jkt 262001
collection forms. The total cost burden
is estimated to be $366,163.
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
E:\FR\FM\11JYN1.SGM
11JYN1
56878
Federal Register / Vol. 89, No. 133 / Thursday, July 11, 2024 / Notices
EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN
Total burden
hours
Form name
Average
hourly
wage rate **
Total burden
cost
1. Structural Assessment .............................................................................................................
2. AHRQ Medical Office Survey on Patient Safety Culture MOSOPS (brick-and-mortar only).
a. Physicians ........................................................................................................................
b. Other Health Practitioners ................................................................................................
3. Participant Experience Survey ................................................................................................
4. Semi-structured qualitative interviews .....................................................................................
5. Antibiotic Prescription Data Template .....................................................................................
75
a $119.54
$8,966
219
219
63
18
4,050
a 119.54
c 76.79
26,179
7,455
7,115
2,152
311,000
Total ......................................................................................................................................
4,644
........................
366,163
b 34.04
a 119.54
a 119.54
** Annualized number of respondents is based on maximum practices recruited, assuming 50% of the practices are telemedicine-only and 50%
are brick-and-mortar, and 75% response rate for forms 1 and 3, 50% response rate for form 2, and 90% response rate for forms 4 and 5.
** National Compensation Survey: Occupational wages in the United States May 2023 ‘‘U.S. Department of Labor, Bureau of Labor Statistics:’’
https://www.bls.gov/oes/current/oes_stru.htm.
a Based on the mean wages for 29–1229 Physicians and Surgeons, All Other.
b Based on the mean wages for 29–9099 Other Healthcare Practitioners and Technical Occupations: Healthcare Practitioners and Technical
Workers, All Other.
c Based on an average of the mean wages for 29–1229 Physicians and Surgeons, All Other and 29–9099 Other Healthcare Practitioners and
Technical Workers: Healthcare Practitioners and Technical Workers, All Other.
Request for Comments
In accordance with the Paperwork
Reduction Act, 44 U.S.C. 3501–3520,
comments on AHRQ’s information
collection are requested with regard to
any of the following: (a) whether the
proposed collection of information is
necessary for the proper performance of
AHRQ’s health care research and health
care information dissemination
functions, including whether the
information will have practical utility;
(b) the accuracy of AHRQ’s estimate of
burden (including hours and costs) of
the proposed collection(s) of
information; (c) ways to enhance the
quality, utility and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information upon the
respondents, including the use of
automated collection techniques or
other forms of information technology.
Comments submitted in response to
this notice will be summarized and
included in the Agency’s subsequent
request for OMB approval of the
proposed information collection. All
comments will become a matter of
public record.
Dated: July 8, 2024.
Marquita Cullom,
Associate Director.
khammond on DSKJM1Z7X2PROD with NOTICES
[FR Doc. 2024–15250 Filed 7–10–24; 8:45 am]
BILLING CODE 4160–90–P
VerDate Sep<11>2014
19:08 Jul 10, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifier: CMS–10398]
Emergency Reinstatement: Public
Information Collection Requirements
Submitted to the Office of Management
and Budget (OMB)
Centers for Medicare &
Medicaid Services.
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is requesting
that this information collection request
(ICR), for the reinstatement of certain
generic information collection requests
(GenICs) be processed under the
emergency Paperwork Reduction Act of
1995 (PRA) clearance process. Such
GenICs are without change. We seek
emergency reinstatement since we
believe that public harm is reasonably
likely to ensue if the normal, nonemergency clearance procedures are
followed.
SUMMARY:
Comments must be received by
July 16, 2024.
ADDRESSES: Submitting Comments.
When commenting, please reference the
applicable collection’s CMS ID number
and/or the OMB control number (both
numbers are listed below under the
SUPPLEMENTARY INFORMATION caption).
To be assured consideration, comments
and recommendations must be
submitted in any one of the following
ways and by the applicable due date:
1. Electronically. We encourage you to
submit comments through the Federal
eRulemaking portal at the applicable
DATES:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
web address listed below under the
caption
under ‘‘Docket Information.’’ If needed,
instructions for submitting such
comments can be found on that website.
2. By regular mail. Alternatively, you
can submit written comments to the
following address:
CMS, Office of Strategic Operations
and Regulatory Affairs (OSORA),
Division of Regulations Development,
Attention: CMS–10398/OMB 0938–
1148, Room C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
Obtaining Documents. To obtain
copies of supporting statements and any
related forms and supporting documents
for the collections listed in this notice,
we encourage you to access the Federal
eRulemaking portal at the applicable
web address listed below under the
SUPPLEMENTARY INFORMATION caption
under ‘‘Docket Information’’ and
‘‘Docket Web Address.’’ If needed,
follow the online instructions for
accessing the applicable docket and the
documents contained therein.
FOR FURTHER INFORMATION CONTACT: For
general information contact William N.
Parham at 410–786–4669. For policy
related questions contact the individual
listed below under the SUPPLEMENTARY
INFORMATION caption under ‘‘Docket
Information.’’
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from
OMB for each collection of information
that they conduct or sponsor. The term
‘‘collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c).
Generally, it applies to voluntary and
mandatory requirements that are related
to any one or more of the following
activities: the collection of information,
SUPPLEMENTARY INFORMATION
E:\FR\FM\11JYN1.SGM
11JYN1
Agencies
[Federal Register Volume 89, Number 133 (Thursday, July 11, 2024)]
[Notices]
[Pages 56875-56878]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-15250]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Agency Information Collection Activities: Proposed Collection;
Comment Request
AGENCY: Agency for Healthcare Research and Quality, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice announces the intention of the Agency for
Healthcare Research and Quality (AHRQ) to request that the Office of
Management and Budget (OMB) approve a revision of the currently
approved information collection project: ``The AHRQ Safety Program for
Telemedicine: Improving the Diagnostic Process and Improving Antibiotic
Use.''
This proposed information collection was previously published in
the Federal Register on April 29th, 2024 and allowed 60 days for public
comment. AHRQ received no substantive
[[Page 56876]]
comments from members of the public. The purpose of this notice is to
allow an additional 30 days for public comment.
DATES: Comments on this notice must be received by August 12, 2024.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function.
Copies of the proposed collection plans, data collection
instruments, and specific details on the estimated burden can be
obtained from the AHRQ Reports Clearance Officer.
FOR FURTHER INFORMATION CONTACT: Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427-1477, or by email at
[email protected].
SUPPLEMENTARY INFORMATION:
Proposed Project
AHRQ Safety Program for Telemedicine: Improving Antibiotic Use
This Information Collection Request (ICR) is for a revision to the
AHRQ Safety Program for Telemedicine: Improving the Diagnostic Process
and Improving Antibiotic Use. These changes include the removal of the
Diagnostic Process Cohort, updates to the Improving Antibiotic Use Data
Collection Tools and changing the name of the project to the ``AHRQ
Safety Program for Telemedicine: Improving Antibiotic Use.'' The OMB
control number for the AHRQ Safety Program for Telemedicine is 0935-
0265 and will expire on April 30, 2026. Supporting documents can be
downloaded from OMB's website at: https://www.reginfo.gov/public/do/PRAViewICR?ref_nbr=202303-0935-001. AHRQ is requesting a new expiration
date, three years from approval.
Since the project received OMB approval, there have been two
developments that require changes to the project's goals and design.
First, the Improving the Diagnostic Process Cohort was canceled because
there was insufficient recruitment. Second, the materials approved by
OMB for the Improving Antibiotic Use Cohort included a single version
of the Structural Assessment and Participant Experience Survey, to be
completed by all participants in the improving antibiotic use cohort.
However, following pre-recruitment discussions with AHRQ's Technical
Expert Panel (TEP) and potential participants, it was learned that the
target audience for the improving antibiotic use cohort is comprised of
healthcare providers from two distinctly different settings (brick-and-
mortar and telemedicine-only) settings. Providers that practice in
brick-and-mortar settings provide care both in-person and via
telemedicine whereas providers that practice in telemedicine-only
settings provide care exclusively using telemedicine. Based on this
information AHRQ decided to create separate data collection tools, one
for providers in a brick-and-mortar setting, and one for providers in
telemedicine only. Practices and providers receive information about
the program from newsletters, listservs, and direct outreach through
public and private organizations. They attend an information webinar
and may join the program if interested and eligible.
As in the currently approved design, the program will incorporate
CUSP strategies to improve antibiotic prescribing in telemedicine. The
new program goals are to:
Identify best practices in implementing interventions to
improve antibiotic use in telemedicine.
Determine how best to adapt CUSP to enhance antibiotic use
in telemedicine.
Use a CUSP approach to design and implement the
interventions for improving antibiotic use across telemedicine
practices.
Reduce inappropriate antibiotic prescribing among
telemedicine practices.
To achieve these goals the following data collections will be
implemented:
1. Structural Assessment Antibiotic Use Cohort--There will be two
versions of the Structural Assessment, one for providers in a brick-
and-mortar setting, and one for providers in telemedicine only. Both
versions ask the same questions but vary slightly in how they refer to
the practice. The assessment asks about the practice's characteristics,
experience related to antibiotic stewardship activities, and any
existing supports the practice may have in place that are intended to
improve antibiotic prescribing. The assessment will be administered to
the Safety Program leader/champion at each participating brick-and-
mortar practice or telemedicine-only organization at baseline (pre-
intervention) and at the end of the intervention. The results will be
used to assess changes in the practice's infrastructure and capacity to
implement the Safety Program over time. The data will provide
information about any existing quality improvement initiatives
currently in place, their existing infrastructure and capacity to carry
out the program, as well as changes in the infrastructure and quality
improvement activities as a result of participation in the Safety
Program.
2. Medical Office Survey on Patient Safety Culture (MOSOPS): As
currently approved, the Safety Program for Telemedicine included
completion of the MOSOPS by all participating staff across all
participating practices. In this revision, AHRQ will administer the
MOSOPS to HCPs practicing in brick-and-mortar settings only. The MOSOPS
was designed to assess key characteristics of HCPs working in-person in
a single medical office and results are unlikely to be reliable or
valid if administered among HCPs practicing in telemedicine-only
settings. The MOSOPS will be administered to all participating staff at
brick-and-mortar practices at baseline (pre-intervention) and at the
end of the intervention. The survey collects information on patient
safety issues, patient safety culture, medical errors, and event
reporting. The data will be used to assess changes in safety culture
following implementation of the Safety Program.
3. Participant Experience Survey Antibiotic Use Cohort--Based on
feedback from the TEP and conversations with telemedicine-only
organizations, this revision includes changes to the Participant
Experience Survey as well as unique versions for brick-and-mortar and
telemedicine-only participants. The survey will be administered to the
clinical leader/champion at each practice at the end of the program
(post-intervention). The survey will assess how participants approached
implementation of the Safety Program.
4. Semi-Structured Interviews Antibiotic Use Cohort--A proportion
of practices from both brick-and-mortar practices and telemedicine-only
organizations will be selected to participate in telephone/virtual
discussions to understand the facilitators and barriers to implementing
the Safety Program. This interview guide includes four core domains
that are intended to capture characteristics of health care providers
(physicians, nurse practitioners, and physician assistants) and their
perception of the AHRQ Safety Program for Telemedicine: Improving
Antibiotic Use (``the Safety Program'') on pre- and post-implementation
changes. All interviews will occur at the end of the intervention
period.
5. Antibiotic Prescription Data Template Antibiotic Use Cohort--
Each
[[Page 56877]]
month starting at baseline (pre-intervention) until the end of the
intervention, each participating practice will extract antibiotic
prescribing data from their electronic health record (EHR) system. The
data will be submitted quarterly using a secure online data submission
portal. The prescribing data will evaluate changes in antibiotic usage,
clinical outcomes, and other effectiveness measures resulting from
participation in the Safety Program. Based on feedback from
participants in the prior AHRQ Safety Program, this updated version
includes revisions to the EHR template to simplify the data requested
in the template from aggregate to visit-level. Participating practices
will submit two key types of data related to antibiotic prescribing:
(1) Total antibiotic prescriptions per 100 respiratory tract infection
telemedicine visits and (2) Antibiotic prescriptions per 100
antibiotic-inappropriate respiratory tract infection telemedicine
visits. This data will be an important way for the practice to monitor
its prescribing practices throughout the course of the program and will
be used by the assessment team to monitor and describe prescribing
trends across practices enrolled in the program.
This study is being conducted by AHRQ through its contractor, NORC
at the University of Chicago and Johns Hopkins Medicine, pursuant to
AHRQ's statutory authority to conduct and support research on
healthcare and on systems for the delivery of such care, including
activities with respect to the quality, effectiveness, efficiency,
appropriateness, and value of healthcare services and with respect to
quality measurement and improvement. 42 U.S.C. 299a(a)(1) and (2).
Method of Collection
To minimize respondent burden and to permit the electronic
submission of survey responses and data collection forms, the
structural assessment, AHRQ MOSOPS, participant experience survey, and
antibiotic prescription data template will be web-based and deployed
using a well-designed, low burden, and respondent-friendly survey
administration process. In addition, the EHR data extracted by practice
staff that are requested for this program may already be collected by
practices as part of their ongoing quality improvement initiatives.
Practices will receive access to the online data collection platform
and detailed instructions on completing the online forms and EHR data
submissions.
Estimated Annual Respondent Burden
Exhibit 1 shows the estimated annualized burden hours for the
respondents' time to participate in this project.
1. Structural Assessment Antibiotic Use Cohort--The assessment will
be administered twice to the Safety Program leader/champion at each
participating brick-and-mortar practice or telemedicine-only
organization, once at baseline (pre-intervention) and again at the end
of the intervention. AHRQ expects 188 respondents at each
administration. The Assessment requires 12 minutes to complete.
2. Medical Office Survey on Patient Safety (MOSOPS)--The MOSOPS
will be completed by all participating staff at brick-and-mortar
practices to assess patient safety issues, medical errors, and event
reporting practices. The survey will be completed twice, once at
baseline (pre-intervention) and at the end of the intervention to
measure the changes in patient safety culture resulting from
participation in the Safety Program. The survey will be completed by
438 staff members at each administration and requires 30 minutes to
complete.
3. Participant Experience Survey Antibiotic Use Cohort--The
Participant Experience Survey will be administered once to the Safety
Program leader/champion at the end of the intervention to assess
participant engagement and progress; understand providers' experience
using materials and participating in the Safety Program; and identify
processes used and changes made to implement and sustain the Safety
Program. The survey is estimated to require 20 minutes to complete.
4. Semi-Structured Interviews Antibiotic Use Cohort--Semi-
structured interviews will be conducted at the end of the intervention
among clinical and professional support staff from a sample of
practices to collect qualitative information on the implementation of
the program. Interviews will be conducted with 18 participating
practices/organizations and requires one hour to complete.
5. Antibiotic Prescription Data Template Antibiotic Use Cohort--The
Antibiotic Prescription Data Template will be completed each month and
submitted quarterly starting in the baseline (pre-intervention) period
until the end of the intervention to measure changes in antibiotic
usage resulting from the intervention. The data will be extracted from
the practice/organization's electronic health records, by a staff
member, and entered into the data template. AHRQ expects 225 practices/
organizations to extract data monthly for 18 months. Each monthly data
extraction should require one hour of a staff members time.
The total burden for the respondents' time to participate in this
research is estimated to be 4,644 hours.
Exhibit 1--Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of
Form name Number of responses per Hours per Total burden
respondents * respondent response hours
----------------------------------------------------------------------------------------------------------------
1. Structural Assessment........................ 188 2 12/60 75
2. MOSOPS (brick-and-mortar only)............... 438 2 30/60 438
3. Participant Experience Survey................ 188 1 20/60 63
4. Semi-structured interviews................... 18 1 1 18
5. Antibiotic Prescription Data Template........ 225 18 1 4,050
---------------------------------------------------------------
Total....................................... 1,057 na na 4,644
----------------------------------------------------------------------------------------------------------------
* Annualized number of respondents is based on maximum practices recruited, assuming 50% of the practices are
telemedicine-only and 50% are brick-and-mortar, and 75% response rate for forms 1 and 3, 50% response rate for
form 2, and 90% response rate for forms 4 and 5.
Exhibit 2 shows the estimated annualized cost burden based on the
respondents' time to complete the data collection forms. The total cost
burden is estimated to be $366,163.
[[Page 56878]]
Exhibit 2--Estimated Annualized Cost Burden
----------------------------------------------------------------------------------------------------------------
Total burden Average hourly Total burden
Form name hours wage rate ** cost
----------------------------------------------------------------------------------------------------------------
1. Structural Assessment........................................ 75 \a\ $119.54 $8,966
2. AHRQ Medical Office Survey on Patient Safety Culture MOSOPS
(brick-and-mortar only)........................................
a. Physicians............................................... 219 \a\ 119.54 26,179
b. Other Health Practitioners............................... 219 \b\ 34.04 7,455
3. Participant Experience Survey................................ 63 \a\ 119.54 7,115
4. Semi-structured qualitative interviews....................... 18 \a\ 119.54 2,152
5. Antibiotic Prescription Data Template........................ 4,050 \c\ 76.79 311,000
-----------------------------------------------
Total....................................................... 4,644 .............. 366,163
----------------------------------------------------------------------------------------------------------------
** Annualized number of respondents is based on maximum practices recruited, assuming 50% of the practices are
telemedicine-only and 50% are brick-and-mortar, and 75% response rate for forms 1 and 3, 50% response rate for
form 2, and 90% response rate for forms 4 and 5.
** National Compensation Survey: Occupational wages in the United States May 2023 ``U.S. Department of Labor,
Bureau of Labor Statistics:'' https://www.bls.gov/oes/current/oes_stru.htm.
\a\ Based on the mean wages for 29-1229 Physicians and Surgeons, All Other.
\b\ Based on the mean wages for 29-9099 Other Healthcare Practitioners and Technical Occupations: Healthcare
Practitioners and Technical Workers, All Other.
\c\ Based on an average of the mean wages for 29-1229 Physicians and Surgeons, All Other and 29-9099 Other
Healthcare Practitioners and Technical Workers: Healthcare Practitioners and Technical Workers, All Other.
Request for Comments
In accordance with the Paperwork Reduction Act, 44 U.S.C. 3501-
3520, comments on AHRQ's information collection are requested with
regard to any of the following: (a) whether the proposed collection of
information is necessary for the proper performance of AHRQ's health
care research and health care information dissemination functions,
including whether the information will have practical utility; (b) the
accuracy of AHRQ's estimate of burden (including hours and costs) of
the proposed collection(s) of information; (c) ways to enhance the
quality, utility and clarity of the information to be collected; and
(d) ways to minimize the burden of the collection of information upon
the respondents, including the use of automated collection techniques
or other forms of information technology.
Comments submitted in response to this notice will be summarized
and included in the Agency's subsequent request for OMB approval of the
proposed information collection. All comments will become a matter of
public record.
Dated: July 8, 2024.
Marquita Cullom,
Associate Director.
[FR Doc. 2024-15250 Filed 7-10-24; 8:45 am]
BILLING CODE 4160-90-P